Stock Market Impact: Zealand Pharma A/S shares sank more than 26% on Monday after the Phase III SYNCHRONIZE‑1 trial data for its obesity drug survodutide showed high discontinuation rates due to gastrointestinal adverse events.
Trial Details – SYNCHRONIZE‑1: Conducted over 76 weeks in 725 adults with obesity or overweight without Type 2 diabetes. Weight loss reached up to 16.6% (efficacy estimand) versus 3.2% for placebo. Discontinuation due to adverse events occurred in 23.7% (3.6 mg dose) and 24.8% (6 mg dose) compared with 5.4% on placebo; gastrointestinal events were 17.8% and 20.2% versus 2.9% for placebo.
Placebo Arm Issue: 16.5% of patients on placebo used a prohibited GLP‑1 receptor agonist, inflating placebo weight loss and narrowing the apparent treatment gap.
Body‑Composition Sub‑Study (MRI, n=75): At 6 mg, survodutide reduced visceral fat by 34% relative to 11.8% for placebo, liver fat by 63.1% versus 24.5% for placebo, and contributed ≤10.8% of total tissue‑mass change to lean mass.
SYNCHRONIZE‑MASLD Trial: 48‑week study in 218 adults with obesity and metabolic dysfunction‑associated steatotic liver disease met both co‑primary endpoints. ≥30% relative liver‑fat reduction achieved by 84.2% of survodutide patients vs 24.3% placebo; body weight fell 12.2% vs 1% placebo (efficacy estimand). Liver‑fat normalization (<5%) reached 61% vs 5.7% placebo.
Commercial Terms: Zealand Pharma is eligible for high single‑ to low double‑digit percentage royalties on global survodutide sales and up to €315 million in potential outstanding milestone payments.
Licensing: Survodutide is licensed to Boehringer Ingelheim, which is solely responsible for global development and commercialization.
Analyst Commentary: Wolfe Research, holding an “outperform” rating, set a DKK 750 price target, implying a 129.8% upside from the pre‑drop close, and highlighted the high discontinuation rate as a risk to the drug’s risk/benefit profile.
Other Observations: No references to monetary policy, interest rates, liquidity, or fiscal measures were made in the announcement.
